Abbott Advances Technologies for Treating Abnormal Heart Rhythms with New Clinical Data

Scientific Sessions/Conferences April 25, 2026

Abbott presented new late-breaking clinical data demonstrating the effectiveness of its pulsed field ablation (PFA) and conduction system pacing (CSP) technologies for treating abnormal heart rhythms at the Heart Rhythm Society 2026. The findings include six-month results from the FlexPulse IDE study, showcasing positive outcomes from the TactiFlex™ Duo Ablation Catheter and supporting evidence for new CSP devices such as UltiSynq™ and AVEIR™ systems. These advancements highlight Abbott’s commitment to improving treatment options for complex atrial fibrillation (AFib) and other heart rhythm disorders.